Desreumaux, P. Et Al. 2023. Tofacitinib in Ulcerative Colitis: The Relationship Between OCTAVE Induction Week 8 Symptomatic Remission and OCTAVE Sustain Week 52 Remission. Annual Scientific Meeting of the American-College-of-Gastroenterology (ACG) , (Vancouver, Canada).

Desreumaux, P., AKYÜZ, F., Ha, C., Bouzidi, A., Tamzali, A., Gardiner, S., ... Wu, J.(2023). Tofacitinib in Ulcerative Colitis: The Relationship Between OCTAVE Induction Week 8 Symptomatic Remission and OCTAVE Sustain Week 52 Remission . Annual Scientific Meeting of the American-College-of-Gastroenterology (ACG), Vancouver, Canada

Desreumaux, Pierre Et Al. "Tofacitinib in Ulcerative Colitis: The Relationship Between OCTAVE Induction Week 8 Symptomatic Remission and OCTAVE Sustain Week 52 Remission," Annual Scientific Meeting of the American-College-of-Gastroenterology (ACG), Vancouver, Canada, 2023

Desreumaux, Pierre Et Al. "Tofacitinib in Ulcerative Colitis: The Relationship Between OCTAVE Induction Week 8 Symptomatic Remission and OCTAVE Sustain Week 52 Remission." Annual Scientific Meeting of the American-College-of-Gastroenterology (ACG) , Vancouver, Canada, 2023

Desreumaux, P. Et Al. (2023) . "Tofacitinib in Ulcerative Colitis: The Relationship Between OCTAVE Induction Week 8 Symptomatic Remission and OCTAVE Sustain Week 52 Remission." Annual Scientific Meeting of the American-College-of-Gastroenterology (ACG) , Vancouver, Canada.

@conferencepaper{conferencepaper, author={Pierre Desreumaux Et Al. }, title={Tofacitinib in Ulcerative Colitis: The Relationship Between OCTAVE Induction Week 8 Symptomatic Remission and OCTAVE Sustain Week 52 Remission}, congress name={Annual Scientific Meeting of the American-College-of-Gastroenterology (ACG)}, city={Vancouver}, country={Canada}, year={2023}}